Nyxoah - Gilde Healthcare



Mont-Saint-Guibert, Belgium

Neurostimulation for sleep apnea
Since: 2016

Belgian Healthtech company focused on the treatment of sleep apnea.

Nyxoah is focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, bilateral hypoglossal nerve stimulation therapy for OSA, the world’s most common sleep disordered breathing condition which is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

In Western countries alone there are over 1 million new eligible OSA patients each year who require treatment but have failed the current gold standard, Continuous Positive Airway Pressure (CPAP) therapy, which requires a bulky machine and wearing a mask at night. Neurostimulation is an effective and well-established therapy for OSA that can address this unmet need.

More Nyxoah news

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Gilde Healthcare portfolio company Nyxoah realizes successful IPO at Nasdaq

Gilde Healthcare Company Nyxoah BETTER SLEEP trial reaches its primary endpoints

Nyxoah and Vanderbilt University enter exclusive licensing agreement

Nyxoah announces full-body MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

Nyxoah raises up to €85 million (US$100M) in successful initial public offering

Nyxoah announces intention to launch an Initial Public Offering on Euronext Brussels

Nyxoah publishes positive clinical data

Nyxoah receives European CE Mark approval for the Genio™ system to treat sleep apnea

Nyxoah raises €15 million in financing round led by Australian MedTech corporate Cochlear (ASX: COH)

Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah